

*Going beyond Commitment,*



## SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

### UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31st DECEMBER 2011

( in lacs), except share data

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2011	30/09/2011	31/12/2010	31/12/2011	31/12/2010	31/3/2011
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Sales & Services	4,872.27	4,812.88	3,206.48	14,158.98	10,533.18	15,104.22
	Less : Excise duty	8.57	8.50	11.11	27.62	54.42	60.84
	<b>Net Income from Sales &amp; Services</b>	<b>4,863.70</b>	<b>4,804.38</b>	<b>3,195.37</b>	<b>14,131.36</b>	<b>10,478.76</b>	<b>15,043.38</b>
2	<b>Expenditure</b>						
	a) Decrease (Increase) in stock in trade	(879.48)	(92.73)	(398.64)	(982.83)	(24.10)	(53.43)
	b) Consumption of raw materials	2,125.68	1,678.55	1,404.30	5,658.34	3,703.56	5,549.85
	c) Purchase of traded goods	-	-	-	-	-	-
	d) Personnel cost	583.66	594.21	408.85	1,649.34	1,249.77	1,782.08
	e) Depreciation	138.27	140.02	137.64	417.01	408.39	544.55
	f) Other expenditure - Manufacturing Exps	736.75	585.70	523.87	1,876.52	1,473.02	2,082.72
	- Selling Exps	41.64	83.00	24.81	173.05	140.21	261.95
	- Administrative Exps	679.22	297.03	377.99	1,258.18	769.66	1,029.44
	- R & D Exps	858.01	877.31	780.68	2,483.14	2,347.61	3,114.35
	- Provision for MTM on Forward Contracts	660.83	541.86	-	1,202.69	-	-
	g) Total	4,944.58	4,704.95	3,259.50	13,735.44	10,068.12	14,311.51
3	<b>Profit from operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>(80.88)</b>	<b>98.43</b>	<b>(64.13)</b>	<b>395.92</b>	<b>410.64</b>	<b>731.87</b>
4	Other Income	156.28	162.28	6.14	338.84	42.92	125.74
5	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	<b>75.40</b>	<b>260.71</b>	<b>(57.99)</b>	<b>734.76</b>	<b>453.56</b>	<b>857.61</b>
6	Interest	213.52	192.97	129.85	570.07	389.41	532.17
7	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>(138.12)</b>	<b>67.74</b>	<b>(187.84)</b>	<b>164.69</b>	<b>64.15</b>	<b>325.44</b>
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit/Loss from Ordinary Activities before tax (7-8)</b>	<b>(138.12)</b>	<b>67.74</b>	<b>(187.84)</b>	<b>164.69</b>	<b>64.15</b>	<b>325.44</b>
10	Tax Expenses	(267.57)	(188.38)	(299.81)	(556.97)	(625.73)	(714.50)
11	<b>Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)</b>	<b>129.45</b>	<b>256.12</b>	<b>111.97</b>	<b>721.66</b>	<b>689.88</b>	<b>1,039.94</b>
12	Extraordinary Items	-	-	-	-	-	-
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>129.45</b>	<b>256.12</b>	<b>111.97</b>	<b>721.66</b>	<b>689.88</b>	<b>1,039.94</b>
14	Paid-up equity share capital (Face Value of the Share)	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00
15	Reserves excluding revaluation Reserve Reserves as per balance sheet of previous accounting year	-	-	-	-	-	11,506.42
16	<b>Earning Per Share (EPS)</b>						
	a) Basic and diluted EPS before extra ordinary items	0.11	0.22	0.10	0.62	0.59	0.89
	b) Basic and diluted EPS after extra ordinary items to date and for the previous year (not annualised)	0.11	0.22	0.10	0.62	0.59	0.89
17	Public share holdings						
	- Number of shares	42,679,160	42,679,160	42,858,960	42,679,160	42,858,960	42,858,960
	- Percentage of Share holding	36.56%	36.56%	36.72%	36.56%	36.72%	36.72%
18	<b>Promoters and promoter group Shareholding</b>						
	a) Pledged / Encumbered - Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of Shares (on promoter & promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of Shares (on total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered - Number of shares	74,052,828	74,052,828	73,873,028	74,052,828	73,873,028	73,873,028
	- Percentage of Shares (on promoter & promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (on total share capital of the company)	63.44%	63.44%	63.28%	63.44%	63.28%	63.28%

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							
PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended	
	31/12/2011	30/09/2011	31/12/2010	31/12/2011	31/12/2010	31/3/2011	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	<b>SEGMENT REVENUE :-</b>						
	a) Manufacturing (CRAMS)	4,600.69	4,358.64	2,478.68	13,274.95	8,703.62	12,675.22
	b) Services (DDDSS)	271.58	454.23	727.80	884.03	1,829.56	2,429.01
	c) Research & Development	-	-	-	-	-	-
	<b>Net Sales from Operations</b>	<b>4,872.27</b>	<b>4,812.87</b>	<b>3,206.48</b>	<b>14,158.98</b>	<b>10,533.18</b>	<b>15,104.23</b>
2	<b>SEGMENT RESULTS :-</b>						
	Profit/(Loss) before tax and interest:						
	a) Manufacturing (CRAMS)	1,959.14	1,512.59	591.55	4,799.04	2,405.03	3,494.25
	b) Services (DDDSS)	111.12	279.78	425.94	459.45	870.93	1,063.51
	c) Research & Development	(858.01)	(877.31)	(780.68)	(2,483.14)	(2,347.61)	(3,114.35)
	<b>TOTAL</b>	<b>1,212.25</b>	<b>915.06</b>	<b>236.81</b>	<b>2,775.35</b>	<b>928.35</b>	<b>1,443.41</b>
Less:	i) Interest	213.52	192.97	129.85	570.07	389.41	532.17
	ii) Other Un-allocable exps net off un-allocable Income	1,136.85	654.35	294.80	2,040.59	474.79	585.80
	<b>Total Profit Before Tax</b>	<b>(138.12)</b>	<b>67.74</b>	<b>(187.84)</b>	<b>164.69</b>	<b>64.15</b>	<b>325.44</b>
3	<b>CAPITAL EMPLOYED</b>						
	(Segment Assets - Segment Liabilities)						
	a) Manufacturing (CRAMS)	14,356.18	12,566.39	11,722.43	14,356.18	11,722.43	12,075.70
	b) Services (DDDSS)	312.27	381.73	949.42	312.27	949.42	629.97
	c) Research & Development	2,973.76	3,438.29	3,409.89	2,973.76	3,409.89	3,506.95
	d) Net assets which are not segmented and used commonly	4,103.06	3,569.93	2,231.64	4,103.06	2,231.64	3,036.80
	<b>TOTAL</b>	<b>21,745.27</b>	<b>19,956.34</b>	<b>18,313.38</b>	<b>21,745.27</b>	<b>18,313.38</b>	<b>19,249.42</b>

Notes:

- 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 31st,Jan' 2012
- 2) Status of investor grievance :- Opening bal : 01, Received : 30, Resolved : 31, Closing bal : Nil
- 3) Previous years figures have been regrouped / reclassified whenever necessary.
- 4) The limited review has been completed by the Statutory Auditors.
- 5) Provision for MTM Loses pertain to Forward Contracts entered for covering the future receivables in USD.

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad  
Date : 31/01/2012

VENKAT JASTI  
Chairman & CEO

*We Deliver*